Back to Search Start Over

A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation.

Authors :
Singh, Umesh
Bernstein, Jonathan a.
Lorentz, Holly
Sadoway, Tara
Nelson, Victoria
Patel, Piyush
Salapatek, anne Marie
Source :
International Archives of Allergy & Immunology. Aug2017, Vol. 173 Issue 3, p153-164. 12p. 2 Diagrams, 2 Charts, 4 Graphs.
Publication Year :
2017

Abstract

Background: Nonallergic vasomotor rhinitis (NAVMR) has been considered a diagnosis by exclusion due to unknown mechanisms or lack of diagnostic biomarkers. Methods: To determine clinical responses and biological pathways in NAVMR subjects challenged to cold dry air (CDA) in an environmental exposure chamber (EEC) pre- and posttreatment with azelastine/fluticasone (AzeFlu), 30 NAVMR subjects, prescreened for CDA-induced symptoms (approx. 14 ° C, <15% relative humidity, ×1 h) were randomized to treatment with AzeFlu ( n = 20) or placebo ( n = 10) for 2 weeks. Total nasal symptoms scores, minimum cross-sectional area, cough, and conjunctival redness were recorded at visit 1 (pretreatment) and visit 2 (posttreatment) before, during, and after CDA challenge. At both visits, nasal lavage fluid (NLF) and nasal scrapings (NS) were collected pre- and post- CDA challenge. Substance P, neurokinin-A, and calcitonin gene-related peptide concentrations in NLF were analyzed pre- and postchallenge at each visit. Their relationship with CDA-induced symptoms was determined by statistical analysis. MicroRNA sequencing from NS determined differentially expressed miRNA between the treatment groups post- CDA challenge at each visit. Results: The minimum crosssectional area ( p < 0.05), cough count ( p < 0.05), and substance P ( p < 0.01) improved posttreatment with AzeFlu versus placebo. Gene targets for differentially expressed miRNAs at visit 1 were enriched for biological pathways regulating epithelial ciliogenesis and cell integrity that were modified in the AzeFlu-treated group versus placebo posttreatment. Conclusions: This study demonstrated the feasibility of an EEC model to investigate CDA-induced clinical responses and pathobiology in NAVMR subjects pre- and posttreatment with AzeFlu. NAVMR disease mechanisms for other nonallergic triggers can be investigated similarly. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10182438
Volume :
173
Issue :
3
Database :
Academic Search Index
Journal :
International Archives of Allergy & Immunology
Publication Type :
Academic Journal
Accession number :
124925370
Full Text :
https://doi.org/10.1159/000478698